Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

FDA Approves Secukinumab for Children with Enthesitis-Related Arthritis & PsA

Michele B. Kaufman, PharmD, BCGP  |  Issue: April 2022  |  February 2, 2022

In late 2021, the U.S. Food and Drug Administration (FDA) approved secukinumab (Cosentyx) to treat two conditions in pediatric rheumatology patients: active enthesitis-related arthritis in patients aged four years and older and psoriatic arthritis (PsA) in patients aged 2 years and older.1 Secukinumab is a human IgG1κ monoclonal antibody that binds to interleukin-17A.

Background: The International League of Associations for Rheumatology divides juvenile idiopathic arthritis (JIA) into seven categories based on presentation within the first six months of illness.2 One category is enthesitis-related arthritis, which is an HLA-B27-related JIA characterized by the involvement of the entheses, peripheral joints and axial skeleton. ERA represents 10–16% of all patients with JIA. Compared with other categories of JIA, children with ERA tend to have higher disease activity, greater pain intensity and worse health outcomes. Achieving and maintaining inactive disease is also more difficult for patients with ERA than those in other JIA categories.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Research

Results from the phase 3, double-blind, placebo-controlled JUNIPERA study were used for this FDA approval of secukinumab. In this two-year, three-part study, researchers enrolled 86 children and adolescents aged 2–17 years old with a confirmed diagnosis of ERA or juvenile PsA.3 At baseline, patients were randomized to receive 75 mg of subcutaneous secukinumab if they weighed less than 50 kg and 150 mg if they weighed at least 50 kg. Patients also received this dose at weeks 1, 2, 3, 4, 8 and 12.

Next, the patients who achieved at least a 30% improvement from baseline in at least three of the six core JIA criteria (i.e., a JIA ACR 30 response) were randomized into the double-blind, placebo-controlled part of the study.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients in part 2 received either secukinumab or placebo every four weeks until they experienced disease flare or reached week 100. The primary end point was the time to disease flare. Key secondary end points (e.g., JIA ACR 30, 50, 70, 90, 100, inactive disease, JADAS, enthesitis) were also evaluated, as well as drug safety.

The results: 97 patients were enrolled in the original open-label study, with a mean age of 13 years, with 33.7% of them being girls. Eighty-six of these patients entered into the randomized double-blind part of the study. Fifty-two of these patients had enthesitis-related arthritis, and 34 had juvenile PsA. At the end of part 1, 90% (75 of 83) of patients had achieved a JIA ACR 30 response, and 70% (58 of 83) had achieved a JIA ACR 70 response. (Note: The authors did not mention why the denominators for part 2 of the study were 83 vs. 86 patients.)

At the end of the study, patients with active juvenile PsA who received secukinumab had a significantly longer time to flare, with an 85% reduction in the risk of flare (P<.001) compared with those patients who received placebo. Patients with active ERA treated with secukinumab also had a longer time to flare, with a 53% reduction in the risk of flare compared with patients who received placebo. The patients treated with secukinumab had sustained improvements in signs and symptoms up to week 100.

No new safety signals were identified.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Novartis Cosentyx receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis. Novartis AG. 2021 Dec 23.
  2. Shih Y, Yang Y, Lin C, et al. Enthesitis-related arthritis is the most common category of juvenile idiopathic arthritis in Taiwan and presents persistent active disease. Pediatr Rheumatol Online J. 2019 Aug 23;17(1):58.
  3. Ruperto N, Foeldvari I, Alexeeva E, et al. Efficacy and safety of secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: Primary results from a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 study (JUNIPERA). Ann Rheum Dis. 2021;80:201–202.

Page: 1 2 | Multi-Page
Share: 

Filed under:ConditionsDrug UpdatesPediatric Conditions Tagged with:enthesitis-related arthritis (ERA)FDAFDA approvalPediatricPediatric RheumatologyPsAPsoriatic ArthritissecukinumabU.S. Food and Drug Administration (FDA)

Related Articles

    Case Report: A Psoriatic Arthritis Patient with Dactylitis & Enthesitis

    September 20, 2018

    A 36-year-old woman presented at the Johns Hopkins Arthritis Center for a second opinion regarding a diagnosis of psoriatic arthritis (PsA). One year prior to our evaluation, she had developed pain and stiffness in her hands, feet, knees, ankles, elbows and shoulders. She had mild plaque psoriasis of the scalp and base of the neck,…

    Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

    December 1, 2022

    PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

    Oksana Kuzmina/shutterstock.comx

    Environmental Factors in Pediatric Systemic Autoimmune Diseases

    March 20, 2017

    Systemic autoimmune diseases are thought to result from immune dysregulation in genetically susceptible individuals who were exposed to environmental risk factors. Many studies have identified genetic risk factors for these diseases, but concordance rates among monozygotic twins are 25–40%, suggesting that nonheritable environmental factors play a more prominent role.1,2 Through carefully conducted epidemiologic and other…

    Secukinumab Effective Across the Spectrum of Psoriatic Arthritis

    April 5, 2021

    A posthoc analysis confirms patients with active psoriatic arthritis (PsA) taking secukinumab experience improvement in all signs and symptoms of PsA as measured by the GRAPPA-OMERACT disease activity core domains.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences